CLONAZEPAM Drug Interactions
Also known as: Clonazepam
Clonazepam is a medication used to treat certain types of seizure disorders, including Lennox-Gastaut syndrome and absence seizures. It also helps manage panic disorder, which involves unexpected panic attacks. This medication works by calming overactivity in the brain to reduce seizures and anxiety.CLONAZEPAM has 10 documented drug interactions in our database, including 6 contraindicated, 4 major, 0 moderate, and 0 minor interactions.
6
Contraindicated
4
Major
0
Moderate
0
Minor
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and hypoventilation.
Mechanism
Both buprenorphine (an opioid partial agonist) and clonazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the brainstem respiratory centers, and can potentiate GABAergic neurotransmission, leading to profound sedation and respiratory depression.
Clinical Management
Concomitant use should generally be avoided due to the high risk of serious adverse outcomes, as highlighted by the FDA Black Box Warning. If co-prescription is absolutely necessary, the lowest effective doses should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Consider alternative non-opioid or non-benzodiazepine treatments.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased respiratory rate and depth, hypoxemia, somnolence, confusion, and impaired psychomotor function. The effects can be particularly pronounced in opioid-naive individuals or those with underlying respiratory conditions.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Clonazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS activity.
Clinical Management
Avoid concomitant use of oxycodone and clonazepam due to the high risk of severe adverse outcomes, as highlighted by the FDA Black Box Warning. If co-prescription is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, monitor patients closely for respiratory depression and sedation, and consider naloxone availability. Educate patients and caregivers on the risks and symptoms of respiratory depression.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.
Mechanism
Both tramadol, an opioid analgesic, and clonazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the respiratory drive, mediated through distinct but synergistic pathways.
Clinical Management
Concomitant use is contraindicated due to the high risk of severe adverse outcomes. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest duration possible, and closely monitor for respiratory depression and sedation. Consider naloxone availability and patient education on risk factors.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Both codeine (an opioid analgesic) and clonazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression, primarily by enhancing GABAergic activity (benzodiazepines) and inhibiting neuronal activity through opioid receptor agonism (codeine), resulting in synergistic effects on respiratory drive and sedation.
Clinical Management
Concomitant use of codeine and clonazepam is generally contraindicated due to the high risk of severe adverse outcomes. If no alternative treatments are adequate, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest duration possible, and monitor patients closely for respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms of CNS depression.
The concurrent use of methadone and clonazepam significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may exhibit somnolence, decreased level of consciousness, bradycardia, hypotension, and hypoventilation. This combination can also impair psychomotor function, increasing the risk of falls and accidents.
Mechanism
Methadone, an opioid agonist, primarily acts on mu-opioid receptors, leading to central nervous system (CNS) depression, including respiratory depression. Clonazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also causing CNS depression. The co-administration of these two classes of drugs results in additive CNS and respiratory depressant effects.
Clinical Management
Concomitant use of methadone and clonazepam is generally contraindicated due to the severe risks. If co-administration is absolutely unavoidable, the lowest effective doses of both drugs should be used for the shortest possible duration, with close monitoring for signs of respiratory depression and sedation. Consider non-benzodiazepine alternatives for anxiety or insomnia, or opioid-sparing pain management strategies.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, dizziness, extreme drowsiness, slowed or difficult breathing, and hypoxemia.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Clonazepam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor. Concomitant use of these central nervous system (CNS) depressants leads to additive depressant effects, primarily on the respiratory and central nervous systems.
Clinical Management
Concomitant use of tapentadol and clonazepam is generally contraindicated due to the high risk of severe adverse outcomes, including death. If co-prescription is absolutely unavoidable, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for respiratory depression and sedation. Consider alternative treatments that do not involve co-prescribing opioids and benzodiazepines.
Patients may experience severe respiratory depression, leading to hypoxemia, apnea, and potentially respiratory arrest. Profound sedation, somnolence, dizziness, and impaired psychomotor function are common. In severe cases, this interaction can result in coma and death.
Mechanism
Fentanyl, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Clonazepam, a benzodiazepine, enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects of both drugs lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Avoid co-prescription if possible. If co-administration is unavoidable, prescribe the lowest effective doses and for the shortest duration possible. Closely monitor patients for signs of respiratory depression, sedation, and hypotension, especially during initiation or dose escalation. Educate patients and caregivers on the risks and symptoms to watch for, and provide naloxone if appropriate.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. These effects can be life-threatening if not promptly recognized and managed.
Mechanism
Both morphine (an opioid agonist) and clonazepam (a benzodiazepine) are central nervous system (CNS) depressants. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The co-administration of these agents leads to an additive and synergistic depressant effect on the CNS, particularly on respiratory drive and consciousness.
Clinical Management
Avoid co-prescribing opioids and benzodiazepines whenever possible. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone for opioid overdose reversal. Consider alternative non-opioid or non-benzodiazepine therapies.
Concomitant use can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and hypoxemia. The risk is heightened in opioid-naive patients or those with underlying respiratory conditions.
Mechanism
Hydromorphone, an opioid agonist, binds to mu-opioid receptors in the central nervous system (CNS), leading to CNS depression, including respiratory depression and sedation. Clonazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, resulting in further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Avoid concomitant use of hydromorphone and clonazepam whenever possible. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms, and consider prescribing naloxone for at-risk patients.
The co-administration of oxymorphone and clonazepam significantly increases the risk of severe adverse outcomes including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. This interaction poses a life-threatening risk, particularly in opioid-naive individuals or those with underlying respiratory compromise.
Mechanism
Oxymorphone, an opioid agonist, and clonazepam, a benzodiazepine, both depress the central nervous system (CNS). Opioids bind to mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Avoid concomitant use of oxymorphone and clonazepam due to the high risk of severe adverse effects, as highlighted by an FDA Black Box Warning. If co-prescription is unavoidable, use the lowest effective doses for the shortest possible duration, and monitor patients closely for signs of respiratory depression and sedation. Consider alternative treatments that do not involve concurrent opioid and benzodiazepine use.
For complete prescribing information:
View full CLONAZEPAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.